Dana (Canada)

In this paper, a direct bonded GaN intelligent power module (IPM) with liquid cooling is demonstrated. A half bridge module with GaN high electron mobility transistors (HEMTs) is bonded on active metal brazed (AMB) substrates which are pre-brazed on a copper liquid-cooled heat exchanger. The design of this power module, such as the selections of the GaN dies and the placement of the GaN dies with respect to the AMB dimensions, is determined based on thermal simulations, estimated electrical parasitics and experiments. The prototype GaN IPMs are demonstrated in a buck converter configuration. The modules are tested up to 110 W with top surface temperature of the PCB module kept below 125°c, measured by an infrared camera (FLIR). The proposed IPM with liquid cooling offers an effective packaging solution for electric vehicle applications.

Importance: The Participation and Environment Measure Plus (PEM+) is a new electronic health application to help caregivers contribute to client-centered and participation-focused care planning for their young child. The PEM+ is designed to help caregivers build on their participation assessment by determining priority activities, setting specific goals, and identifying strategies for goal attainment. Objective: To examine the usability of the PEM+. Design: A single-arm usability trial. Setting: Two early intervention and early childhood educational programs. Participants: Six caregivers of children ages 0–3 yr with developmental delay and receiving rehabilitation services. Intervention: Caregivers who were eligible and enrolled were given access to the PEM+ for 1 wk and instructed to complete one iteration. Outcomes and Measures: Usability was assessed according to caregivers’ report of PEM+’s technical effectiveness and ease of use, ease of learning, and user satisfaction via the Usefulness, Satisfaction, and Ease of Use questionnaire. Results: All caregivers completed the PEM+ online once and in its entirety (mean completion time = 13.6 min). Mean technical effectiveness ratings ranged from 5.7 to 6.3 out of 7.0, and mean ease of use, ease of learning, and user satisfaction ratings were 4.4, 5.4, and 4.2 out of 6.0, respectively. Conclusions and Relevance: Caregivers of young children can navigate the PEM+. Trends in survey feedback informed optimizations for the PEM+ before further feasibility testing. What This Article Adds: This study provides preliminary evidence for a promising tool that can help to customize the way practitioners partner with families to create a plan for occupational therapy services.

3521 Background: IGF-1 has been shown to stimulate neoplastic cell growth and inhibit apoptosis, whereas IGFBP-3 inhibits the bioavailability of IGF-1 and has independent proapoptotic activity. In epidemiologic studies, higher levels of plasma IGF-1 increase the risk of CRC whereas higher levels of IGFBP-3 have been associated with decreased risk. Methods: We examined plasma levels of IGF-1, IGFBP-3, and C-peptide among 527 patients participating in a randomized trial of first-line chemotherapy for metastatic CRC (Intergroup trial N9741). Three chemotherapy arms were evaluated in this multicenter study: 5-FU/leucovorin/CPT-11, 5-FU/leucovorin/oxaliplatin, and oxaliplatin/CPT-11. Data on prognostic factors and body size as well as plasma specimens were collected at baseline. Results: Controlling for IGF-1 levels, treatment arm, and other prognostic factors, increasing IGFBP-3 levels were associated with a higher response rate (RR) to chemotherapy (P = 0.01; RR = 51% vs. 34% comparing highest to lowest quartiles). Compared to subjects in the lowest quartile of IGFBP-3, the hazard ratio (HR) for tumor progression for those in the highest quartile was 0.71 (95% CI, 0.53–0.95) (median TTP = 302 vs. 218 days, comparing highest to lowest quartiles; P for trend = 0.003). Neither IGF-1 nor C-peptide were significantly related to RR or TTP after adjusting for other covariates. Moreover, there was no statistical interaction between IGFBP-3 levels and treatment assignment. In preliminary analyses, higher plasma IGFBP-3 was positively associated with overall survival with an over 6 month difference in median survival comparing highest to lowest quartiles (HR = 0.50, 95% CI, 0.35–0.73). Mature data on TTP and overall survival will be available for presentation. Conclusions: Higher baseline levels of circulating IGFBP-3 predict an improved outcome among patients with metastatic CRC. The IGF pathway may represent an important target for future treatment strategies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Oncology Pfizer Oncology Pharmacia, Inc. (now Pfizer)